SCHEMBL17299752

SCHEMBL17299752

CC(C)[C@H](C)C(=O)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.52
ATM Q13315 1/20 0.52
USP2 O75604 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HPGD P15428 1/20 0.44
EPHX2 P34913 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RECQL P46063 1/20 0.42
EPHX1 P07099 1/20 0.42
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1669097 0.85 HTT (0.55) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL4546718 0.84 HTT (0.54) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL17708312 0.84 HTT (0.54) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL3720687 0.84 HTT (0.54) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL17292388 0.83 HTT (0.50) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL15533550 0.83 HTT (0.50) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL698803 0.82 USP2 (0.69) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL18294 0.82 USP2 (0.69) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL3982522 0.82 HTT (0.52) HTTATMUSP2SMN1; SMN2MAPT
SCHEMBL2085854 0.82 HTT (0.52) HTTATMUSP2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 US disclosed
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 HTT 1780/4885ATM 4145/4885USP2 1906/4885
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 HTT 1780/4885ATM 4145/4885USP2 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.